Abstract 739P
Background
The DESTINY-PanTumor02 trial demonstrated efficacy of HER2-directed antibody drug conjugates (ADCs) in the treatment of gynecologic malignancies, including EEA. Trial eligibility was determined utilizing HER2 IHC gastric criteria, but many institutions historically use breast criteria for IHC interpretations. As neither scoring system has been validated in gynecologic neoplasms, our study seeks to compare them in EEA.
Methods
Blinded pathology review of HER2 IHC (4B5) from 263 randomly selected EEAs was performed by two board-certified pathologists utilizing gastric and breast criteria. Results of the two scoring systems were compared (Positive [P]: intensity 3+, >10% [breast] or ≥10% [gastric] tumor cell staining, Equivocal [E]: 2+, >10% [breast] or ≥10% [gastric], Low/Negative [N]: >1+, ≤10% [breast] or <10% [gastric], or any percentage of 1+). Tumors were analyzed for ERBB2 copy number amplification by DNA (592-gene or whole exome) sequencing and statistical significance determined using unpaired T-test.
Results
Of HER2 P cases, 96% (49/51) were concordant between breast/gastric criteria, median of 13.0 copies of ERBB2. HER2 E tumors showed a lower rate of concordance with 51% (30/59) concordant cases, median of 2.5 copies of ERBB2. Of discordant HER2 E tumors, 44% (26/59) of E cases were N by breast/E by gastric (1.8 median copies, p < 0.02 vs concordant cases). HER2 N cases were 86% (155/182) concordant (1.9 median copies, p = 0.96 vs N by breast/E by gastric cases).
Conclusions
While gastric and breast criteria demonstrated 96% concordance in identifying EEAs positive for HER2 overexpression, equivocal staining was more often documented with gastric scoring. This greater frequency of equivocal results may suggest a preference for gastric criteria in the assessment of EEA, matching trial inclusion criteria where clinical benefit of HER2 ADCs has been established in patients with HER2 equivocal tumors. Table: 739P
Concordance and discordance of HER2 IHC calls by gastric and breast criteria
IHC Call | Gastric | |||
P | E | N | ||
Breast | P | 49 | 1 | 0 |
E | 1 | 30 | 1 | |
N | 0 | 26 | 155 |
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M.G. Evans: Financial Interests, Personal, Invited Speaker: Caris Life Sciences; Financial Interests, Personal, Full or part-time Employment: Caris Life Sciences; Financial Interests, Personal, Stocks/Shares: Caris Life Sciences. H. Krause: Financial Interests, Institutional, Full or part-time Employment, I am a full time employee at Caris Life Sciences: Caris Life Sciences. A. Elliott: Financial Interests, Personal, Full or part-time Employment: Caris Life Sciences. C. Mathews: Financial Interests, Institutional, Research Funding: AstraZeneca, Tesaro/GSK, Astellas Pharma, Seattle Genetics, Deciphera, Moderna, Regeneron, Roche/Genentech, Pfizer, Laekna Therapeutics, EMD Serono, Merck, Genmab, Avenge Bio, Zentalis, ImmunoGen, Elucida Oncology, Artios, Volastra Therapeutics, AADI, Repare Therapeutics. S. Wei: Financial Interests, Personal, Other, board member of molecular tumor board of Caris Life Sciences: Caris Life Sciences. J. Hechtman: Financial Interests, Personal, Full or part-time Employment: Caris Life Sciences; Financial Interests, Personal, Speaker, Consultant, Advisor: Pfizer. D. Bryant: Financial Interests, Institutional, Full or part-time Employment, Senior Medical Director of Pathology: Caris Life Sciences; Financial Interests, Personal, Stocks/Shares, Own stock and have stock options: Caris Life Sciences. M. Oberley: Financial Interests, Personal, Full or part-time Employment: Caris Life Sciences; Financial Interests, Personal, Stocks/Shares: Caris Life Sciences. M.A. Powell: Financial Interests, Personal, Speaker, Consultant, Advisor: GSK, Merck, Eisai, AstraZeneca, Seagen, Immunogenicity. P.H. Thaker: Financial Interests, Personal, Advisory Board: Merck, GSK, Seagen, Immunon, ImmunoGen, Novocure, Zentalis; Financial Interests, Personal, Other, consulting: Caris, Verastem; Financial Interests, Personal, Other, DSMB committee: Iovance; Financial Interests, Institutional, Research Grant: Merck, GSK; Financial Interests, Institutional, Coordinating PI: Zentalis, Seagen, ImmunoGen; Financial Interests, Institutional, Local PI: Verastem, Genelux. All other authors have declared no conflicts of interest.
Resources from the same session
671P - LuMIERE: A phase I/II study evaluating safety, dosimetry, and preliminary activity of [177Lu]Lu-FAP-2286 in patients with advanced solid tumors
Presenter: Jonathan McConathy
Session: Poster session 01
672P - Inference failure with synthetic arms: Empirical application to phase III oncology trials
Presenter: Alexander Decruyenaere
Session: Poster session 01
673P - Project Optimus for dose optimization: Implementation strategies for your trial from the statistician’s standpoint
Presenter: Miguel Pereira
Session: Poster session 01
674P - Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs
Presenter: Sebastian Albers
Session: Poster session 01
675P - Evaluation of the safety and efficacy of JSKN003 in patients with advanced HER2-positive (IHC 3+) solid tumors (excluding breast cancer)
Presenter: Lin Shen
Session: Poster session 01
678TiP - A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations
Presenter: Charlotte Lemech
Session: Poster session 01
679TiP - Cancer Research UK phase I/IIa trial of the prostaglandin E2 (PGE2) receptor 4 (EP4) antagonist HTL0039732 as monotherapy and in combination with immunotherapy in patients (pts) with advanced solid tumors
Presenter: Debashis Sarker
Session: Poster session 01
680TiP - A phase I/IIa first-in-human clinical trial evaluating MDX2001, a multi-specific antibody in patients with advanced solid tumor malignancies
Presenter: Anna Minchom
Session: Poster session 01
681TiP - A phase I/II, open label, multi-center, non-randomized dose escalation and dose expansion study of AMXI-5001 in patients with advanced malignancies
Presenter: Lee Rosen
Session: Poster session 01